Edgewise Therapeutics CFO Michael Nofi Sells $202K of Stock
Michael Nofi, CFO, sold 4,442 shares of Edgewise Therapeutics, Inc. at $45.43 a share, worth $202K in total on Nov 10, 2026. Shares held after the trade: 6,495 (-40.6%).
Edgewise Therapeutics reported 109,482,763 shares of common stock outstanding as of October 31, 2026. The company is focusing its resources on the development of EDG-7500 and EDG-15400 following the Sevasemten Sale, which has impacted its operating expenses and cash position.
Edgewise Therapeutics reported Q3 2026 financial results, highlighting a $1.348 billion gain from the sale of sevasemten to Servier. The company ended the quarter with $1.74B in cash and is on track to initiate a Phase 3 trial for EDG-7500 in HCM by year-end 2026.
“Our third quarter reflects continued execution across both cardiovascular programs. In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026.”
Kevin Koch, Ph.D., President and Chief Executive Officer